Pathophysiology of CAS

Different triggers, shared downstream biology

Why this spoke matters

Secondary cold agglutinin syndrome is often described as “cold agglutinin disease caused by something else.” That shorthand is useful, but incomplete.

The downstream biology may look familiar: an IgM antibody binds red cells at lower temperatures, red cells agglutinate in cooler vascular beds, complement is activated, and hemolysis or cold-induced circulatory symptoms may follow.

But the upstream biology is different.

In primary cold agglutinin disease (CAD), the antibody is usually a persistent monoclonal IgM produced by a clonal marrow B-cell process. In secondary cold agglutinin syndrome (CAS), the cold antibody appears in association with another condition, such as infection, autoimmune disease, or overt lymphoid malignancy.¹

That distinction changes how clinicians interpret the antibody, how long they expect the process to last, what they look for next, and what they treat.

The core principle is this:

Secondary CAS is defined by clinical context, not by a single antibody feature; trajectory helps determine whether the initial classification remains appropriate.

This matters because the first label may not be the final label. A cold agglutinin that appears during infection may disappear as the infection resolves. A cold agglutinin associated with autoimmune disease may persist as long as immune activation persists. A cold agglutinin associated with lymphoma may track with the underlying malignancy. And occasionally, a presentation that initially appears secondary may later reveal a more durable clonal source.

Shared downstream biology

Once a clinically significant cold-reactive antibody binds red cells, the downstream biology can resemble primary CAD.²

The pathway has two related but distinct arms:

Agglutination and circulatory symptoms

• IgM binds red-cell surface carbohydrate antigens at lower temperatures
• red cells agglutinate in cooler, low-shear vascular beds
• microvascular flow becomes impaired
• acrocyanosis, livedo, Raynaud-like symptoms, or cold-induced pain may follow

Complement activation and hemolysis

• IgM binding activates the classical complement pathway
• C3 fragments deposit on red cells
• complement-opsonized red cells are cleared, usually through hepatic extravascular hemolysis
• more severe complement activation may occasionally contribute to intravascular hemolysis

This shared downstream biology explains why patients with secondary CAS can resemble patients with primary CAD at the bedside. Both may have anemia, jaundice, acrocyanosis, livedo, Raynaud-like symptoms, dark urine during exacerbations, or worsening symptoms with cold exposure.

But similar downstream biology does not mean identical disease.

The source of the antibody determines whether the process is likely to be transient, reactive, malignancy-associated, or self-sustaining.

Thermal amplitude and clinical expression

Thermal amplitude is central in secondary CAS, just as it is in primary CAD.

A cold agglutinin that binds only at very low temperatures may have little clinical effect. An antibody that binds at temperatures reached in peripheral circulation can produce clinically important agglutination, complement activation, or hemolysis.³

This is why antibody titer alone is insufficient. Titer measures how much antibody is present; thermal amplitude measures whether that antibody binds at temperatures the patient’s circulation actually reaches.

Clinical expression depends on:

• thermal amplitude
• antibody concentration
• complement-fixing efficiency
• persistence of antibody production
• degree of cold exposure
• patient-specific vascular and inflammatory context

In secondary CAS, thermal amplitude helps explain why some infection-associated cold agglutinins are harmless laboratory findings, while others cause symptomatic hemolysis or cold-induced circulatory symptoms.

The upstream question

The most important question in secondary CAS is not simply:

Does the patient have a cold agglutinin?

It is:

Why is this cold agglutinin present, and will the source persist?

That question separates secondary CAS from primary CAD and also separates different forms of secondary CAS from one another.

A post-infectious cold agglutinin may disappear as the infection resolves.

A cold agglutinin associated with autoimmune disease may persist as long as immune activation persists.

A cold agglutinin associated with lymphoma may track with the underlying malignancy.

In each case, the same downstream mechanism may be present, but the upstream driver is different.

Post-infectious cold agglutinin syndrome

Post-infectious CAS is a classic setting in which cold agglutinins arise as part of an acute immune response.

The best-known associations are:

• Mycoplasma pneumoniae
• Epstein–Barr virus
• other respiratory or viral infections

In this setting, cold agglutinins are often transient, frequently polyclonal or oligoclonal, and usually fade as the infection resolves.⁴

The immunology is not always a simple one-antigen, one-antibody story. Polyclonal activation is the broad frame; within it, infection can promote cold agglutinins through overlapping mechanisms:

• inflammatory bystander activation of autoreactive B cells
• cross-reactive IgM responses against red-cell carbohydrate antigens
• transient expansion of B-cell clones that contract after the infection resolves

These mechanisms are not mutually exclusive. They describe different ways an acute immune response can generate cold-reactive antibodies.

This is why polyclonal does not mean random. A broad infection-driven immune response can still include antibodies that recognize related red-cell carbohydrate structures.

Classically, Mycoplasma pneumoniae is associated with anti-I cold agglutinins, whereas Epstein–Barr virus has been associated with anti-i patterns. In this terminology, I refers to the adult I antigen and i to the fetal-type i antigen on red cells. These associations are useful teaching anchors, but they should not be treated as absolute rules.⁵

Post-infectious cold agglutinins typically:

• appear during or shortly after infection
• are often polyclonal or oligoclonal
• have often lower thermal amplitude, although clinically significant cases can occur
• cause mild, transient, or self-limited hemolysis
• improve over weeks to months
• rarely require disease-specific therapy

The practical point is simple:

The presence of a cold agglutinin after infection is common; clinically significant cold agglutinin syndrome is much less common.

Post-infectious cold agglutinins are often benign, but not all cold agglutinins are transient, low-risk, or self-limited. Persistence beyond the expected recovery window, especially with ongoing hemolysis, should prompt reassessment.

Autoimmune or inflammatory-associated CAS

Secondary CAS can also occur in association with autoimmune or inflammatory conditions, such as systemic lupus erythematosus, Sjögren syndrome, rheumatoid arthritis, or other systemic immune disorders.⁶

In this setting, the cold antibody process may reflect ongoing immune activation rather than a marrow-confined CAD-type clone. The antibody may be polyclonal, oligoclonal, or difficult to classify clearly, depending on the underlying disease and the methods used to study it.

The clinical pattern depends on whether the associated inflammatory condition resolves, fluctuates, or persists.

Typical clues include:

• cold antibody–mediated hemolysis occurring in the setting of known autoimmune disease
• disease activity tracking with systemic inflammation
• fluctuating antibody strength or hemolysis over time
• partial improvement when the underlying immune condition is controlled

This category is important because persistence does not automatically mean primary CAD.

Persistence means the clinician should ask a better question:

Is this a prolonged reactive process, ongoing autoimmune or inflammatory disease, malignancy-associated hemolysis, or an emerging clonal cold agglutinin disorder?

Lymphoma-associated cold agglutinin syndrome

Lymphoma-associated CAS is different from post-infectious CAS.

It is called “secondary” because cold antibody–mediated hemolysis occurs in the setting of an overt lymphoid malignancy or clinically apparent lymphoproliferative disorder. But the antibody may still be monoclonal or produced by a clonal B-cell population.⁷

This is a common source of confusion.

Secondary does not mean polyclonal.

Secondary means the cold agglutinin syndrome occurs in association with another clinically defined condition.

In lymphoma-associated CAS, hemolysis may persist or relapse in parallel with the malignancy. Durable control often requires attention to the underlying lymphoid disorder, because the antibody source may be embedded in the neoplastic process.

This differs from primary CAD, where a small marrow-confined clonal B-cell process is part of the disease definition and overt lymphoma is absent at presentation. The presence of a small marrow clone alone should not automatically reclassify primary CAD as secondary CAS. Classification depends on the full clinicopathologic picture, including clinical exam, imaging, marrow morphology, and whether an overt lymphoid malignancy is present.

The boundary can be subtle. Primary CAD is itself associated with a usually indolent marrow B-cell clone. If overt lymphoma is present, or if it emerges over time, the case may be reclassified clinically as secondary cold agglutinin syndrome. But the biology may be continuous rather than abruptly different.⁸

The useful teaching point is:

Primary CAD and lymphoma-associated CAS are separated by clinicopathologic context, not by the simple presence or absence of clonality.

Why persistence matters

Persistence is one of the most important clinical signals in cold antibody–mediated disease.

But persistence does not automatically mean primary CAD.

Persistent or recurrent hemolysis in an apparent secondary CAS should prompt reassessment for:

• a prolonged reactive process
• ongoing autoimmune or inflammatory disease
• malignancy-associated cold agglutinin hemolysis
• an emerging or previously undetected clonal B-cell process
• mixed immune mechanisms

This is especially important when the initial diagnosis was made during an infection. Some patients truly have transient post-infectious cold agglutinins. Others initially appear post-infectious but later reveal a more durable antibody source.

Practical triggers for reassessment include:

• hemolysis that persists beyond the expected post-infectious recovery period
• falling hemoglobin or ongoing transfusion requirement
• rising bilirubin or LDH
• increasing cold-induced circulatory symptoms
• higher or increasing thermal amplitude, when measured
• new lymphadenopathy, splenomegaly, B symptoms, or other systemic features

Classification may therefore need to be revisited as the clinical trajectory becomes clearer over time.

Shared mechanism, different treatment logic

Because the downstream biology overlaps, supportive principles overlap.

Patients with clinically significant secondary CAS may require:

• cold avoidance
• warming measures
• warmed blood products or fluids when transfusion is needed
• evaluation for hemolysis
• monitoring for anemia, jaundice, dark urine, or circulatory symptoms

But treatment logic differs because the source differs.

In post-infectious CAS, disease is often self-limited. Management is usually supportive while the infection resolves.

In autoimmune or inflammatory-associated CAS, control of the underlying immune condition may reduce the cold antibody process.

In lymphoma-associated CAS, management often depends on treating the underlying malignancy or lymphoproliferative disorder.

Complement-directed therapy may be relevant in selected severe cases, but most evidence for agents such as sutimlimab comes from primary CAD, so use in secondary CAS requires careful clinical judgment and extrapolation. Complement inhibition does not eliminate the antibody source. Clone-directed or lymphoma-directed therapy may address the source, but it may not immediately reverse complement already fixed on circulating red cells.⁹

These strategies act at different levels and are often complementary rather than interchangeable.

Thus, management requires asking which layer is dominant:

• the trigger
• the antibody source
• complement-mediated hemolysis
• cold-induced agglutination
• microvascular symptoms
• the underlying associated disease

The same downstream pathway does not imply the same therapeutic strategy.

Table. Primary CAD and secondary cold agglutinin syndromes: shared downstream biology, different upstream drivers

Feature	Primary CAD	Post-infectious CAS	Autoimmune/inflammatory CAS	Lymphoma-associated CAS
Clinical context	no overt associated disorder driving the syndrome	occurs during or after infection	occurs with systemic autoimmune or inflammatory disease	occurs with overt lymphoid malignancy
Antibody source	clonal marrow B-cell process	acute immune response	ongoing immune activation	malignant or clinically apparent lymphoproliferative process
Typical antibody pattern	usually monoclonal IgM	often polyclonal or oligoclonal IgM	variable, often reactive	may be monoclonal or clonal
Trajectory	chronic or relapsing	usually self-limited	may fluctuate or persist with underlying disease	may persist or relapse with malignancy
Shared downstream biology	cold IgM binding, agglutination, complement activation, C3 deposition, hemolysis	same downstream pathway if clinically significant	same downstream pathway if clinically significant	same downstream pathway if clinically significant
Treatment logic	complement-directed and/or clone-directed therapy when treatment is needed	usually supportive, treat infection if needed	treat underlying immune disease and hemolysis severity	treat underlying malignancy and hemolysis severity
Key caution	small marrow clone does not equal overt lymphoma	detection is not disease	persistence does not automatically mean primary CAD	secondary does not mean polyclonal

Clinical synthesis

Secondary cold agglutinin syndrome is not a single biologic entity. It is a clinical category defined by cold antibody–mediated hemolysis occurring in another disease context.

Its downstream logic overlaps with primary CAD: cold-reactive IgM binds red cells, agglutination may impair flow, complement activation produces C3 deposition, and hemolysis may follow.

Its upstream logic differs: infection, inflammation, autoimmune disease, or overt lymphoid malignancy shapes the antibody source and determines whether the process is likely to resolve, persist, or relapse.

The practical principle is:

Source determines classification. Thermal amplitude and complement determine phenotype. Trajectory determines whether the initial label still fits.

Key takeaways

• secondary CAS is context-defined: it occurs when cold antibody–mediated hemolysis appears in association with another condition.
• post-infectious CAS is often transient: infection-associated cold agglutinins are frequently polyclonal or oligoclonal and usually self-limited.
• detection is not disease: cold agglutinins after infection are common, but clinically significant CAS is much less common.
• secondary does not mean polyclonal: lymphoma-associated CAS may involve monoclonal or clonal antibody production.
• persistence should prompt reassessment: ongoing hemolysis may reflect prolonged reactive disease, autoimmune inflammation, malignancy-associated hemolysis, or emerging clonal disease.
• downstream biology converges: once clinically significant IgM binds red cells in the cold, thermal amplitude, complement activation, and agglutination shape the phenotype.
• treatment follows the source and the phenotype: supportive care, treatment of the associated condition, complement inhibition, or clone/lymphoma-directed therapy may each matter depending on the case.